Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nabriva Therapeutics PLC

www.nabriva.com

Latest From Nabriva Therapeutics PLC

Heralding Change: Product Pipeline Advances To Watch Out For In Q3

Key events that could move innovative product candidates nearer the market in the third quarter of 2019 are highlighted in a new Biomedtracker/Meddevicetracker report.

Approvals Clinical Trials

After The Peak Of 2018’s US FDA Approval Record, 2019 Looks Like A Valley

FDA’s second half 2019 user fee calendar features almost 30 novel agents, but another record-breaking tally is out of reach.

Approvals Drug Approval Standards

EU Accelerated Assessment Tracker

Accelerated assessment requests at the European Medicines Agency.

Europe Drug Review

Keeping Track: US FDA Approves Sanofi’s Dengvaxia, But Heron’s HTX-011 And Nabriva’s Contepo Fall Short

The latest drug development news and highlights from our US FDA Performance Tracker.
Approvals Drug Review
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Antibiotic Research Institute
  • Nabriva Therapeutics AG
  • 1641640
  • Nabriva Therapeutics Forschungs GMBH
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Ireland
  • Parent & Subsidiaries
  • Nabriva Therapeutics PLC
  • Senior Management
  • Ted Schroeder, CEO
    Gary Sender, CFO
    Francesco Maria Lavino, Chief Commercial Officer
    Jennifer Schranz, MD, CMO
    Steven Gelone, MD, CSO & Head, Bus. Dev.
  • Contact Info
  • Nabriva Therapeutics PLC
    Phone: (43) 1 649 2000
    25-28 North Wall Quay
    Dublin, 1
    Ireland
Advertisement
Advertisement
UsernamePublicRestriction

Register